Nothing new. Dr. T did say that, based on the fast track status, they could start the phase III trial as soon as the interim data came out (assuming the phase II shows efficacy) .They have 6 million in the bank, and a cash burn of 500K per quarter, so they are funded for a long time
I think Ohr will present again in 2 weeks at the Retinal conference in Toronto; perhaps somebody can ask Dr. Elman about the 1 month data from his trial. The company won't be valued properly until they release human results; it could be 2 week or 1 month data. It doesn't matter because once they prove the eye drop can accumulate in the choroid, it will keep sticking there for as long as the patient applies the drop.
I've only heard one other presentation, but I noticed during Q&A, when asked about partnering, Taraporewala commented that the potential to attract partners was part of the reason for including an interim look as part of the PhII trial. Thats the first I heard of that. I guess if results were robust and somebody threw a billion and a half his way (ala Molecular Partners/AGN), as much as he'd like to go it alone, it might be a wise hedge to partner.
To clarify the statement "once they prove the eye drop can accumulate in the choroid"; well they have proved the drops accumulate in the rabbit choroid via an scleral route, but the investment community wants Ohr to show them that humans with wet amd respond to the drops. If they do that, the company is as good as gold, but until then, it's a speculative investment only and not for widows and orphans.